Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs

NYSE:PFE

Pfizer Inc (PFE)

26.17
+0.57 (2.23%)
as of Jun 11, 2026, 8:00:00 pm Market Open.
322 watching
0
PAST TOP PICK
(A Top Pick July 21/06 Up 1%.) Pays a 5% dividend. His model price is $41.35, a 71% positive differential.
DON'T BUY
Has been a very frustrating stock to have. Doesn't seem to be able to get out of its own way.
HOLD
Just reported numbers that were a little bit lighter than expectations. They also reaffirmed their view for next year that they expect to make back the shortfall later in the year. This knee-jerk reaction is an opportunity. 4.5% new.
DON'T BUY
Doesn't like the business models of pharmaceutical companies. Can be hit by generics, lawsuits, etc.. Prefers business models with downside protection. After the next US election, expect there will be severe regulations on pharmaceutical prices.
DON'T BUY
A pure pharmaceutical play and he cautious on this sector. Concerned about lawsuits, patent litigations on generic drugs and also patent expiries.
TOP PICK
The model price is $42, a 63% positive differential. All the drug companies are moving, except this one. Huge cash flows. 5% dividend yield.
TOP PICK
47% positive differential. The most mispriced in the Dow Jones. bonus of 5% dividend yield. They are in around $26.63.
TOP PICK
(A Top Pick July 21/06. Up 14.5%.) 5% yield. His model price is $48.51, a 52% positive differential. The cheapest stock in the Dow Jones.
COMMENT
Is preforming quite well without a lot of fanfare. Thinks it is going to trade to a discount, would rather go to a Sheering or Abbot.
TOP PICK
Hasn't moved but has the most value of similar stocks. Massively mispriced.
COMMENT
Blue chip. Nice dividend. Don't expect too much excitement.
PAST TOP PICK
(A Top Pick May 9/06. Up 4.2%.) Yield gave him another 4%. Sold their consumers products division for $19 billion so have a huge amount of cash on the books. Can't see a lot of downside here.
DON'T BUY
Has value characteristics which is positive, but he can't get comfortable with their largest drug Lipidor going off patent in 2011. Does not all they'll make up for this.
BUY
His value drug play. Growth drug play is Teva Pharmaceutical (TEVA-Q). Pharmaceuticals got the wind kicked out of them a couple of years ago and are now showing some rebound. Very nice yield. Huge cash hoard and are buying back stock and probably will increase dividends again.
BUY ON WEAKNESS
Looks like it is in the process of breaking the downtrend. That was established with the recent higher lows. If you own, he would Hold.
Showing 481 to 495 of 801 entries